WEST PALM BEACH, Fla., May 2, 2012 /PRNewswire/ -- BeesFree, Inc. (OTCBB: BEES), a company which owns patent pending technology that arrests the effects of CCD (Colony Collapse Disorder) on honeybees, announced that the Italian Experimental and Animal Prophylaxis Institute (IZS - Istituto Zooprofilattico Sperimentale) will be conducting an extensive laboratory and field project to test the effectiveness of BeesFree Inc.'s patent-pending technology.
IZS is a government agency operating within the framework of the National Health Service and has the mandate to research innovative solutions to improve animal health, welfare and food safety. IZS also provides services in the diagnosis of animal diseases, and the microbiological, chemical and physical controls over food safety, food production chains and animal feed.
BeesFree Inc. Chief Scientist and inventor of the patent-pending technology, Dr. Francesca del Vecchio, stated, "We believe this study, once completed, will confirm to beekeepers what we already know, that our proprietary chemical compound and delivery technology can effectively improve the health of honeybees and help them mitigate and avoid the effects of CCD. We greatly value our relationship with IZS and look forward to extending this cooperation agreement to cover other solutions relating to the health of honeybees."
IZS Director General, Dr. Remo Rosati stated, "IZS is proud to be associated with BeesFree and test in Italy its novel and innovative patent-pending technology to remedy CCD-related effects. We have allocated a strong team of senior chemical engineers, biologists and veterinaries for the laboratory and field test activities which will be carried out in the framework of this project. We hope this project will significantly contribute to improve our knowledge of effective solutions for honeybee health."
About BeesFree, Inc. (OTCBB:BEES)
BeesFree Inc., a company focused on developing innovativ
|SOURCE BeesFree, Inc.|
Copyright©2010 PR Newswire.
All rights reserved